DRD2, dopamine receptor D2, 1813

N. diseases: 437; N. variants: 42
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE In neuronal cultures, the expression of genes either relevant to SCZ risk (<i>Drd2, Gatad2a</i>, <i>Slc28a1</i>, <i>Cnr1</i>) or indexing co-expression in our module (<i>Btg4</i>, <i>Chit1</i>, <i>Osr1</i>, <i>Gpld1</i>) was significantly modified by gain and loss of Nurr1 and Err1. 31811028 2020
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE Compared with dopamine D2 receptor antagonism that is exhibited by most antipsychotics, partial agonism may result in improved outcomes in major depressive disorder and in schizophrenia. 31406978 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE A total of 7 gene polymorphisms from DRD2 (rs1800497, rs1079597, rs1800498, rs1801028) and 5-HT2 A (rs6313, rs6311, rs6305) were genotyped for their association with schizophrenia. 30389402 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE Cortical D2 dopamine receptor (Drd2) have mostly been examined in the context of cognitive function regulation and neurotransmission modulation of medial prefrontal cortex by principal neurons and parvalbumin positive, fast-spiking, interneurons in schizophrenia. 30295716 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE The study aimed to confirm the association of the schizophrenia genome-wide association study (GWAS) hit rs2514218 located near the DRD2 gene with the risk of the disease and to investigate the relationships between rs2514218 and schizophrenia-related clinical and neuroimaging phenotypes. 31054090 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE The -141C Ins/Del polymorphism in DRD2 (rs1799732) is functional and associated with SCZ. 31176829 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE After Bonferroni correction, there was no association found between DRD2 gene promoter region with schizophrenia risk in the northern Chinese Han population. 30657260 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE These findings underscore the need for a reexamination of cortical DRD2 mediated synaptic plasticity in the context of schizophrenia and other psychotic disorders. 30528973 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE The D2 dopamine receptor (Drd2) is implicated in several brain disorders such as schizophrenia, Parkinson's disease, and drug addiction. 30604007 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE Although the clinical efficacy of dopamine D2 receptor antagonists against positive symptoms of schizophrenia supports the dopamine hypothesis of the disease, the resistance of negative and cognitive symptoms to these drugs implicates other systems in its pathophysiology. 31291870 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. 30332506 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE For example, an elegant roadmap was laid out a year ago by Karolina Kauppi and colleagues wherein they combined a data set for schizophrenia risk genes and another set of genes associated with antipsychotic drug targets.<sup>3</sup> Using this "network biology" approach, they identified four schizophrenia risk genes that were also antipsychotic drug targets (GRM3, DRD2, CHRM4, and CYP2D6); they also found several molecular targets that are not currently connected to antipsychotic drug treatment, providing researchers with some potential targets for novel therapeutics.<sup>4</sup>. 31340894 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE PET imaging of dopamine-D2 receptor internalization in schizophrenia. 28507321 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 AlteredExpression disease BEFREE In a cohort of schizophrenia inpatients CYP2D6 metabolic activity affects mean AP daily dose only in the presence of DRD2 Taq1A polymorphic allele. 29930225 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE NQ treatment in rats increases dopamine D2 receptor sensitivity throughout the animal's lifetime, consistent with schizophrenia. 29444518 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE Effects of the -141C insertion/deletion polymorphism in the dopamine D2 receptor gene on the dopamine system in the striatum in patients with schizophrenia. 29627696 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE Finally, we investigated in HC association of LPFC-amygdala effective connectivity with a genome-wide supported variant increasing genetic risk for SCZ and possibly relevant to emotion processing (DRD2 rs2514218). 28981847 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE The dopaminergic hypothesis of schizophrenia (SZ) postulates that positive symptoms of SZ, in particular psychosis, are due to disturbed neurotransmission via the dopamine (DA) receptor D2 (DRD2). 30546022 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE Human genetic studies also show a significant association of DRD2 polymorphisms with disorders including schizophrenia and Parkinson's disease. 29107444 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE No association between SLC6A2, SLC6A3, DRD2 polymorphisms and schizophrenia in the Han Chinese population. 28454051 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE Antipsychotic drugs, all of which block the dopamine D2 receptor to a greater or lesser extent, are the mainstay for the pharmacological treatment of schizophrenia. 27756689 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE The DRD2 C957T is also associated with schizophrenia, with the C allele being the risk allele. 29945153 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 Biomarker disease BEFREE The purpose of the current exploratory study was to examine the interaction of dopaminergic genes (coding for dopamine receptor D2, DRD2, and for Catecholamine-O-Methyl-Transferase, COMT) with the diagnostic of schizophrenia in (i) the executive control of attention, (ii) selective attention, and (iii) executive functions. 28085950 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 AlteredExpression disease BEFREE Dopamine receptor D2 short, vesicular monoamine transporter (VMAT2) and DAT mRNAs were significantly decreased in schizophrenia, with no change in DRD3 mRNA, DRD3nf mRNA and DAT protein between diagnostic groups. 28094812 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.400 GeneticVariation disease BEFREE A regulatory dopamine 2-receptor gene (DRD2) polymorphism (rs1076560; G>T) has been identified as a genetic risk factor for schizophrenia. 28104410 2017